Stock Of The Day: Where Will The Eli Lilly Rally End?

Core Viewpoint - Eli Lilly's Zepbound drug shows superior weight loss results compared to Novo Nordisk's Wegovy, with a reported 20.2% weight loss versus 13.7% [1] Stock Performance - Eli Lilly shares are experiencing an upward trend following the announcement of Zepbound's efficacy [1] - Historical price peaks for Eli Lilly shares include $956.90 in July, $937.40 in late September, and $846.50 in early November, indicating potential resistance levels [2][3] Market Dynamics - The concept of "buyer's remorse" influences trading behavior, where investors who bought at peak prices may place sell orders when the stock returns to those levels, creating resistance [3] - The saying "Sell at former peaks" is highlighted as a relevant strategy for traders in the context of Eli Lilly's stock performance [3]